Detail akcie Liminatus Rg online

Business Summary: Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Liminatus Pharma Inc revenues was not reported. Net loss decreased 39% to $2M. Lower net loss reflects BIOLOGICAL PRODUCTS segment loss decrease of 78% to $701K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.13 to -$0.08.